The FDA now encourages the use of medication-assisted treatments for opioid addictions to all patients who experience a non-fatal opioid overdose. Additionally, Dr. Gottlieb said the FDA will now back long-term use of these medications — even lifetime use in certain cases. The move from the regulatory agency may meet opposition from some in the field of addiction who feel complete abstinence is the only effective treatment.
“FDA will join efforts to break the stigma associated with medications used for addiction treatment,” Dr. Gottlieb said. “This stigma serves to keep many Americans who are seeking a life of sobriety from reaching their goal. … The stigma reflects a view some have; that a patient is still suffering from addiction even when they’re in full recovery, just because they require medication to treat their illness. This attitude reveals a flawed interpretation of science. It stems from a key misunderstanding many of us have of the difference between a physical dependence and an addiction.”
To read Dr. Gottlieb’s full statement, click here.
More articles on opioids:
Trump to officially declare opioid crisis public health emergency: 7 things to know
Florida sheriff releases video of unconscious couple with baby in backseat to highlight opioid epidemic
Georgia’s most populated county files opioid epidemic lawsuit
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
